Clinical-stage company Neurizon Therapeutics (ASX:NUZ) has announced the appointment of Dan O’Connell as chief financial officer.
Mr O’Connell is a prominent senior executive with over 20 years of experience in multinational companies. He was the chief financial officer (CFO) of Kingsgate Consolidated from July 2024 to February 2025. Just before this, he was interim CFO of Newcrest Mining from December 2022 until it was acquired by the world’s largest gold mining company, Newmont Corporation in November 2023. He previously held roles with BHP Billiton and Ernst & Young.
This company said the appointment will support its transition to in-house financial operations, which is anticipated to yield cost savings and equip it with significant additional expertise as its strategy progresses to advance the commercialisation of its lead drug candidate, NUZ-001.
Mr O’Connell said, “I am thrilled to be joining Neurizon during this crucial phase of its growth trajectory. I look forward to working with the Board, Michael and the broader management team as we transition into late-stage development and prepare for rapid commercialisation. In the near term, my focus will be to utilise my commercial and finance experience to optimise the Company’s in-house finance functions, ensuring the best commercial outcomes for shareholders.”
Neurizon managing director and CEO
Managing Director and CEO Dr Michael Thurn said, “We are very pleased to have attracted someone of Dan’s calibre as CFO. Over a longstanding career, he has developed extensive R&D, commercial and business development experience, as well as cross-border M&A, government and industry relations expertise. We look forward to leveraging his skillset to capitalise on the Company’s next phase of growth.
“Dan’s appointment, alongside the recent additions to our senior leadership team, reflects our continued focus on building a high-performing executive team with the capabilities needed to drive clinical success, commercial execution, and long-term value for our shareholders. It also strengthens the Board’s confidence in the Company’s ability to commercialise NUZ001 as a treatment option, while delivering improved outcomes for patients with neurodegenerative diseases.”
